Claims for Patent: 7,838,498

Summary for Patent: 7,838,498

Title:	Benzylic glycoside derivatives and methods of use
Abstract:	Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
Inventor(s):	Chen; Yuanwei (North Haven, CT), Feng; Yan (Shanghai, CN), Xu; Baihua (Shanghai, CN), Lv; Binhua (Shanghai, CN), Seed; Brian (Derry, NH), Hadd; Michael J. (San Diego, CA), Cheng; Huawei (Shanghai, CN), Sheng; Zelin (Belle Mead, NJ), Xu; Min (Shanghai, CN), Wang; Congna (Shanghai, CN), Du; Jiyan (Shanghai, CN), Zhang; Lili (Shanghai, CN), Xu; Ge (Shanghai, CN), Wu; Yuelin (Shanghai, CN)
Assignee:	Theracos, Inc. (Sunnyvale, CA)
Application Number:	12/060,767
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,838,498
Patent Claims:	1. A compound having the formula: ##STR00096## wherein A is a member selected from the group consisting of oxygen; sulfur; SO; SO.sub.2; methylene optionally substituted with one to two substituents independently selected from halo, hydroxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6 cycloalkyl and C.sub.3-C.sub.6 cycloalkyloxy; C.sub.3-C.sub.51,1-cycloalkylene optionally substituted with one to two substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6 cycloalkyl and C.sub.3-C.sub.6 cycloalkyloxy; and NR.sup.a; V is a member selected from the group consisting of oxygen; sulfur; SO; SO.sub.2; and a single bond; W is a member selected from the group consisting of C.sub.1-C.sub.6 alkylene, C.sub.2-C.sub.6 alkenylene, C.sub.2-C.sub.6 alkynylene, C.sub.3-C.sub.10 cycloalkylene and C.sub.5-C.sub.10 cycloalkenylene; wherein each alkylene, alkenylene, alkynylene, cycloalkylene and cycloalkenylene group of W is optionally partly or completely fluorinated and is optionally mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, C.sub.3-C.sub.6 cycloalkyl, C.sub.3-C.sub.6 cycloalkyloxy, C.sub.5-C.sub.10 cycloalkenyl and C.sub.5-C.sub.10 cycloalkenyloxy, and in cycloalkylene and cycloalkenylene groups of W, one or two methylene groups are optionally replaced independently of one another by O, S, CO, SO, SO.sub.2 or NR.sup.b, and one or two methyne groups of W are optionally replaced by N; X is (i) a member selected from the group consisting of oxygen; sulfur; SO; and SO.sub.2; or (ii) NR.sup.a; when X is (i), Y is a member selected from the group consisting of C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 hydroxyalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.10 cycloalkyl, C.sub.5-C.sub.10 cycloalkenyl, (C.sub.5-C.sub.10 cycloalkenyl)C.sub.1-C.sub.3 alkyl, (C.sub.3-C.sub.10 cycloalkyl)C.sub.2-C.sub.4 alkenyl, C.sub.3-C.sub.6 cycloalkylidenmethyl, (C.sub.5-C.sub.10 cycloalkenyl)C.sub.2-C.sub.4 alkenyl, (C.sub.1-C.sub.4 alkyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.2-C.sub.4 alkenyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.3-C.sub.10 cycloalkyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.5-C.sub.10 cycloalkenyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.1-C.sub.4 alkylamino)C.sub.1-C.sub.3 alkyl, di-(C.sub.1-C.sub.3 alkylamino)C.sub.1-C.sub.3 alkyl, (C.sub.1-C.sub.6 alkyl)carbonyl(C.sub.1-C.sub.3)alkyl, (C.sub.2-C.sub.6 alkenyl)carbonyl(C.sub.1-C.sub.3)alkyl, (C.sub.2-C.sub.6 alkynyl)carbonyl(C.sub.1-C.sub.3)alkyl, (arylcarbonyl)C.sub.1-C.sub.3 alkyl, (heteroarylcarbonyl)C.sub.1-C.sub.3 alkyl, (C.sub.1-C.sub.6 alkylsulfonyl)C.sub.1-C.sub.3 alkyl, (C.sub.2-C.sub.6 alkenylsulfonyl)C.sub.1-C.sub.3 alkyl, (C.sub.2-C.sub.6 alkynylsulfonyl)C.sub.1-C.sub.3 alkyl, (arylsulfonyl)C.sub.1-C.sub.3 alkyl, (heteroarylsulfonyl)C.sub.1-C.sub.3 alkyl, (C.sub.1-C.sub.6 alkyl)aminocarbonyl(C.sub.1-C.sub.3)alkyl, (C.sub.2-C.sub.6 alkenyl)aminocarbonyl(C.sub.1-C.sub.3)alkyl, (C.sub.2-C.sub.6 alkynyl)aminocarbonyl(C.sub.1-C.sub.3)alkyl, (arylaminocarbonyl)C.sub.1-C.sub.3 alkyl, (heteroarylaminocarbonyl)C.sub.1-C.sub.3 alkyl, (C.sub.1-C.sub.6 alkyl)carbonyl, (C.sub.2-C.sub.6 alkenyl)carbonyl, (C.sub.2-C.sub.6 alkynyl)carbonyl, arylcarbonyl and heteroarylcarbonyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions of Y are optionally partly or completely fluorinated and optionally are mono- or disubstituted by identical or different substituents selected from the group consisting of chlorine, hydroxy, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, C.sub.3-C.sub.6 cycloalkyl, C.sub.3-C.sub.6 cycloalkyloxy, C.sub.5-C.sub.10 cycloalkenyl, C.sub.5-C.sub.10 cycloalkenyloxy, and NR.sup.bR.sup.c, and in cycloalkyl and cycloalkenyl groups or portions of Y, one or two methylene groups are optionally replaced independently of one another by O, S, CO, SO, SO.sub.2 or NR.sup.b, and one or two methyne groups are optionally replaced by N, wherein the heterocycle formed by said optional replacement is other than heteroaryl, and wherein when V is a member selected from the group consisting of oxygen, sulfur and a single bond and W is a member selected from the group consisting of C.sub.1-C.sub.6 alkylene, C.sub.2-C.sub.6 alkenylene and C.sub.2-C.sub.6 alkynylene, then Y is other than C.sub.1-C.sub.6 alkyl; when X is (ii), Y is a member selected from the group consisting of C.sub.1-C.sub.6 alkylsulfonyl, C.sub.2-C.sub.6 alkenylsulfonyl, C.sub.2-C.sub.6 alkynylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C.sub.1-C.sub.6 alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, (C.sub.1-C.sub.6 alkyl)carbonyl, (C.sub.2-C.sub.6 alkenyl)carbonyl, (C.sub.2-C.sub.6 alkynyl)carbonyl, arylcarbonyl, heteroarylcarbonyl, (C.sub.1-C.sub.6 alkyl)aminocarbonyl, (C.sub.2-C.sub.6 alkenyl)aminocarbonyl, (C.sub.2-C.sub.6 alkynyl)aminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, (C.sub.1-C.sub.6 alkylsulfonyl)C.sub.1-C.sub.3 alkyl, (C.sub.2-C.sub.6 alkenylsulfonyl)C.sub.1-C.sub.3 alkyl, (C.sub.2-C.sub.6 alkenylsulfonyl)C.sub.1-C.sub.3 alkyl, (arylsulfonyl)C.sub.1-C.sub.3 alkyl, (heteroarylsulfonyl)C.sub.1-C.sub.3 alkyl, (C.sub.1-C.sub.6 alkylsulfinyl)C.sub.1-C.sub.3 alkyl, (arylsulfinyl)C.sub.1-C.sub.3 alkyl, (heteroarylsulfinyl)C.sub.1-C.sub.3 alkyl, (C.sub.1-C.sub.6 alkyl)aminocarbonyl(C.sub.1-C.sub.3)alkyl, (C.sub.2-C.sub.6 alkenyl)aminocarbonyl(C.sub.1-C.sub.3)alkyl, (C.sub.2-C.sub.6 alkynyl)aminocarbonyl(C.sub.1-C.sub.3)alkyl, (arylaminocarbonyl)C.sub.1-C.sub.3 alkyl and (heteroarylaminocarbonyl)C.sub.1-C.sub.3 alkyl; wherein alkyl, alkenyl and alkynyl portions of Y are optionally partly or completely fluorinated, and when R.sup.a is H or (C.sub.1-C.sub.4 alkyl)carbonyl, then Y is other than (C.sub.1-C.sub.6 alkyl)carbonyl or arylcarbonyl; Z is a member selected from the group consisting of oxygen; sulfur; SO; SO.sub.2; 1,1-cyclopropylene; carbonyl; and methylene optionally substituted with one to two substituents independently selected from the group consisting of halo, hydroxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6 cycloalkyl and C.sub.3-C.sub.6 cycloalkyloxy; R.sup.1 is a member selected from the group consisting of hydrogen, halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.10 cycloalkyl, (C.sub.3-C.sub.10)cycloalkyl-(C.sub.1-C.sub.3)alkyl, (C.sub.2-C.sub.4 alkenyl)C.sub.1-C.sub.3 alkyloxy, (C.sub.2-C.sub.4 alkynyl)C.sub.1-C.sub.3 alkyloxy, (C.sub.3-C.sub.10 cycloalkyl)C.sub.2-C.sub.4 alkenyl, C.sub.3-C.sub.6 cycloalkylidenmethyl, (C.sub.3-C.sub.10 cycloalkyloxy)C.sub.1-C.sub.3 alkyl, C.sub.5-C.sub.10 cycloalkenyl, (C.sub.5-C.sub.10)cycloalkenyl-(C.sub.1-C.sub.3)alkyl, (C.sub.1-C.sub.4 alkyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.1-C.sub.4 alkylamino)C.sub.1-C.sub.3 alkyl, di-(C.sub.1-C.sub.3 alkylamino)C.sub.1-C.sub.3 alkyl, aryl, heteroaryl, (C.sub.1-C.sub.4 alkyl)carbonyl, arylcarbonyl, heteroarylcarbonyl, hydroxycarbonyl, aminocarbonyl, (C.sub.1-C.sub.4 alkyl)aminocarbonyl, di-(C.sub.1-C.sub.3 alkyl)aminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4-(C.sub.1-C.sub.4 alkyl)piperazin-1-ylcarbonyl, (C.sub.1-C.sub.4 alkyloxy)carbonyl, amino, C.sub.1-C.sub.4 alkylamino, di-(C.sub.1-C.sub.3 alkyl)amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, 4-(C.sub.1-C.sub.4 alkyl)piperazin-1-yl, (C.sub.1-C.sub.4 alkyl)carbonylamino, arylcarbonylamino, C.sub.1-C.sub.4 alkylsulfonylamino, arylsulfonylamino, heteroarylcarbonylamino, C.sub.1-C.sub.6 alkyloxy, C.sub.3-C.sub.10 cycloalkyloxy, C.sub.5-C.sub.7 cycloalkenyloxy, aryloxy, heteroaryloxy, (aryl)C.sub.1-C.sub.3 alkyloxy, (heteroaryl)C.sub.1-C.sub.3 alkyloxy, C.sub.1-C.sub.4 alkylsulfanyl, C.sub.1-C.sub.4 alkylsulfinyl, C.sub.1-C.sub.4 alkylsulfonyl, C.sub.3-C.sub.10 cycloalkylsulfanyl, C.sub.3-C.sub.10 cycloalkylsulfinyl, C.sub.3-C.sub.10 cycloalkylsulfonyl, C.sub.5-C.sub.10 cycloalkenylsulfanyl, C.sub.5-C.sub.10 cycloalkenylsulfinyl, C.sub.5-C.sub.10 cycloalkenylsulfonyl, arylsulfanyl, arylsulfinyl, arylsulfonyl, hydroxy, cyano and nitro; wherein alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions of R.sup.1 are optionally partly or completely fluorinated and are optionally mono- or disubstituted by identical or different substituents selected from the group consisting of chlorine, hydroxy, C.sub.1-C.sub.3 alkoxy and C.sub.1-C.sub.3 alkyl, and in cycloalkyl and cycloalkenyl groups or portions of R.sup.1, one or two methylene groups are optionally replaced independently of one another by O, S, CO, SO or SO.sub.2, and in N-heterocycloalkyl groups or portions of R.sup.1, a methylene group is optionally replaced by CO or SO.sub.2; R.sup.2 is a member selected from the group consisting of hydrogen, halo, hydroxy, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.10 cycloalkyl, C.sub.5-C.sub.10 cycloalkenyl, C.sub.1-C.sub.4 alkyloxy, C.sub.3-C.sub.10 cycloalkyloxy, cyano and nitro; wherein alkyl and cycloalkyl groups or portions of R.sup.2 are optionally mono- or polysubstituted by fluorine, or in the event that R.sup.1 and R.sup.2 are bound to adjacent C atoms of the phenyl ring, R.sup.1 and R.sup.2 are optionally joined together to form a C.sub.3-C.sub.5 alkylene, C.sub.3-C.sub.5 alkenylene or butadienylene bridge, which is optionally partly or completely fluorinated and optionally mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, C.sub.1-C.sub.3 alkoxy and C.sub.1-C.sub.3 alkyl, and wherein one or two methylene groups are optionally replaced independently of one another by O, S, CO, SO, SO.sub.2 or NR.sup.b, and wherein one or two methyne groups optionally may be replaced by N; R.sup.3 is a member selected from the group consisting of hydrogen, halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.10 cycloalkyl, (C.sub.3-C.sub.10)cycloalkyl-(C.sub.1-C.sub.3)alkyl, C.sub.5-C.sub.10 cycloalkenyl, (C.sub.5-C.sub.10)cycloalkenyl-(C.sub.1-C.sub.3)alkyl, (C.sub.1-C.sub.4 alkyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.3-C.sub.10 cycloalkyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.1-C.sub.4 alkylamino)C.sub.1-C.sub.3 alkyl, di-(C.sub.1-C.sub.3 alkylamino)C.sub.1-C.sub.3 alkyl, (C.sub.3-C.sub.10 cycloalkyl)C.sub.2-C.sub.4 alkenyl, C.sub.3-C.sub.6 cycloalkylidenmethyl, aryl, heteroaryl, (C.sub.1-C.sub.4 alkyl)carbonyl, arylcarbonyl, heteroarylcarbonyl, aminocarbonyl, (C.sub.1-C.sub.4 alkyl)aminocarbonyl, di-(C.sub.1-C.sub.3 alkyl)aminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4-(C.sub.1-C.sub.4 alkyl)piperazin-1-ylcarbonyl, hydroxycarbonyl, (C.sub.1-C.sub.4 alkyloxy)carbonyl, C.sub.1-C.sub.4 alkylamino, di-(C.sub.1-C.sub.3 alkyl)amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, 4-(C.sub.1-C.sub.4 alkyl)piperazin-1-yl, (C.sub.1-C.sub.4 alkyl)carbonylamino, arylcarbonylamino, heteroaryl-carbonylamino, C.sub.1-C.sub.4 alkylsulfonylamino, arylsulfonylamino, C.sub.1-C.sub.6 alkyloxy, C.sub.3-C.sub.10 cycloalkyloxy, C.sub.5-C.sub.7 cycloalkenyloxy, aryloxy, heteroaryloxy, (C.sub.2-C.sub.4 alkenyl)C.sub.1-C.sub.3 alkyloxy, (C.sub.2-C.sub.4 alkynyl)C.sub.1-C.sub.3 alkyloxy, (aryl)C.sub.1-C.sub.3 alkyloxy, (heteroaryl)C.sub.1-C.sub.3 alkyloxy, C.sub.1-C.sub.4 alkylsulfanyl, C.sub.1-C.sub.4 alkylsulfinyl, C.sub.1-C.sub.4 alkylsulfonyl, C.sub.3-C.sub.10 cycloalkylsulfanyl, C.sub.3-C.sub.10 cycloalkylsulfinyl, C.sub.3-C.sub.10 cycloalkylsulfonyl, C.sub.5-C.sub.10 cycloalkenylsulfanyl, C.sub.5-C.sub.10 cycloalkenylsulfinyl, C.sub.5-C.sub.10 cycloalkenylsulfonyl, arylsulfanyl, arylsulfinyl, arylsulfonyl, amino, hydroxy, cyano and nitro; wherein alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions of R.sup.3 are optionally partly or completely fluorinated and are optionally mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, C.sub.1-C.sub.3 alkoxy and C.sub.1-C.sub.3 alkyl, and in cycloalkyl and cycloalkenyl groups or portions of R.sup.3, one or two methylene groups are optionally replaced independently of one another by O, S, CO, SO or SO.sub.2, and in N-heterocycloalkyl groups or portions of R.sup.3, a methylene group is optionally replaced by CO or SO.sub.2; R.sup.4 is a member selected from the group consisting of hydrogen, halo, cyano, nitro, hydroxy, C.sub.1-C.sub.3 alkyl, C.sub.3-C.sub.10 cycloalkyl, C.sub.1-C.sub.3 alkyloxy or C.sub.3-C.sub.10 cycloalkyloxy, wherein alkyl and cycloalkyl groups or portions of R.sup.4 are optionally mono- or polysubstituted by fluorine, and when R.sup.3 and R.sup.4 are bound to adjacent C atoms of the phenyl ring, R.sup.3 and R.sup.4 are optionally joined to form a C.sub.3-C.sub.5 alkylene, C.sub.3-C.sub.5 alkenylene or butadienylene bridge, which is optionally partly or completely fluorinated and is optionally mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, C.sub.1-C.sub.3 alkoxy and C.sub.1-C.sub.3 alkyl, and wherein one or two methylene groups are optionally replaced independently of one another by O, S, CO, SO, SO.sub.2 or NR.sup.b, and wherein one or two methyne groups are optionally replaced by N; R.sup.5 is a member selected from the group consisting of hydrogen, halo, cyano, nitro, hydroxy, C.sub.1-C.sub.3 alkyl, C.sub.3-C.sub.10 cycloalkyl and C.sub.1-C.sub.3 alkyloxy, wherein alkyl and cycloalkyl groups or portions of R.sup.5 are optionally mono- or polysubstituted by fluorine; R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are each independently selected from the group consisting of hydroxy, (C.sub.1-C.sub.18 alkyl)carbonyloxy, (C.sub.1-C.sub.18 alkyl)oxycarbonyloxy, arylcarbonyloxy, aryl-(C.sub.1-C.sub.3 alkyl)carbonyloxy, (C.sub.3-C.sub.10 cycloalkyl)carbonyloxy, hydrogen, halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, (C.sub.3-C.sub.10)cycloalkyl-(C.sub.1-C.sub.3)alkyl, (C.sub.5-C.sub.7)cycloalkenyl-(C.sub.1-C.sub.3)alkyl, aryl-(C.sub.1-C.sub.3)alkyl, heteroaryl-(C.sub.1-C.sub.3)alkyl, C.sub.1-C.sub.6 alkyloxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.3-C.sub.7 cycloalkyloxy, C.sub.5-C.sub.7 cycloalkenyloxy, aryloxy, heteroaryloxy, (C.sub.3-C.sub.7)cycloalkyl-(C.sub.1-C.sub.3)alkyloxy, (C.sub.5-C.sub.7)cycloalkenyl-(C.sub.1-C.sub.3)alkyloxy, aryl-(C.sub.1-C.sub.3)alkyloxy, heteroaryl-(C.sub.1-C.sub.3)alkyloxy, aminocarbonyl, hydroxycarbonyl, (C.sub.1-C.sub.4 alkyl)aminocarbonyl, di-(C.sub.1-C.sub.3 alkyl)aminocarbonyl, (C.sub.1-C.sub.4 alkyloxy)carbonyl, aminocarbonyl-(C.sub.1-C.sub.3)alkyl, (C.sub.1-C.sub.4 alkyl)aminocarbonyl-(C.sub.1-C.sub.3)alkyl, di-(C.sub.1-C.sub.3 alkyl)aminocarbonyl-(C.sub.1-C.sub.3)alkyl, hydroxycarbonyl-(C.sub.1-C.sub.3)alkyl, (C.sub.1-C.sub.4 alkyloxy)carbonyl-(C.sub.1-C.sub.3)alkyl, (C.sub.3-C.sub.7)cycloalkyloxy-(C.sub.1-C.sub.3)alkyl, (C.sub.5-C.sub.7)cycloalkenyloxy-(C.sub.1-C.sub.3)alkyl, aryloxy-(C.sub.1-C.sub.3)alkyl, heteroaryloxy-(C.sub.1-C.sub.3)alkyl, C.sub.1-C.sub.4 alkylsulfonyloxy, arylsulfonyloxy, aryl-(C.sub.1-C.sub.3)alkyl-sulfonyloxy, trimethylsilyloxy, t-butyldimethylsilyloxy, and cyano; wherein alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions of R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are optionally partly or completely fluorinated and are optionally mono- or disubstituted by identical or different substituents selected from the group consisting of chlorine, hydroxy, C.sub.1-C.sub.3 alkoxy and C.sub.1-C.sub.3 alkyl, and in cycloalkyl and cycloalkenyl groups or portions of R.sup.6, R.sup.7, R.sup.8 and R.sup.9, one or two methylene groups are optionally replaced independently of one another by NR.sup.b, O, S, CO, SO or SO.sub.2; each R.sup.a is a member independently selected from the group consisting of H, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl and (C.sub.1-C.sub.4 alkyl)carbonyl, wherein alkyl and cycloalkyl groups or portions of R.sup.a are optionally partly or completely fluorinated; each R.sup.b is a member independently selected from the group consisting of H, C.sub.1-C.sub.4 alkyl and (C.sub.1-C.sub.4 alkyl)carbonyl, wherein alkyl groups or portions of R.sup.b are optionally partly or completely fluorinated; each R.sup.c is a member independently selected from the group consisting of H, C.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.6 cycloalkyl, CHR.sup.dR.sup.e, SO.sub.2R.sup.d, C(O)OR.sup.d and C(O)NR.sup.dR.sup.e, wherein alkyl and cycloalkyl groups of R.sup.c are optionally partly or completely fluorinated; and R.sup.d and R.sup.e each independently represent H or C.sub.1-C.sub.6 alkyl, wherein alkyl groups of R.sup.d and R.sup.e are optionally partly or completely fluorinated; and pharmaceutically acceptable salts thereof. 2. A compound of claim 1, wherein A is oxygen or sulfur. 3. A compound of claim 1, wherein A is oxygen. 4. A compound of claim 1, wherein V is selected from the group consisting of oxygen, sulfur and a single bond. 5. A compound of claim 1, wherein V is oxygen or a single bond. 6. A compound of claim 1, wherein W is selected from the group consisting of C.sub.1-C.sub.6 alkylene and C.sub.3-C.sub.10 cycloalkylene; wherein each alkylene and cycloalkylene group of W is optionally partly or completely fluorinated and is optionally mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, C.sub.1-C.sub.3 alkyl and C.sub.1-C.sub.3 alkoxy, and in cycloalkylene groups of W, one or two methylene groups are optionally replaced independently of one another by O, S, CO, SO, SO.sub.2 or NR.sup.b. 7. A compound of claim 1, wherein W is C.sub.1-C.sub.6 alkylene. 8. A compound of claim 1, wherein X is oxygen or sulfur. 9. A compound of claim 1, wherein Y is selected from the group consisting of C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 hydroxyalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.10 cycloalkyl, C.sub.5-C.sub.10 cycloalkenyl, (C.sub.1-C.sub.4 alkyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.2-C.sub.4 alkenyloxy)C.sub.1-C.sub.3 alkyl and (C.sub.3-C.sub.10 cycloalkyloxy)C.sub.1-C.sub.3 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions of Y are optionally partly or completely fluorinated and optionally are mono- or disubstituted by identical or different substituents selected from the group consisting of chlorine, hydroxy, C.sub.1-C.sub.3 alkyl and C.sub.1-C.sub.3 alkoxy, and in cycloalkyl and cycloalkenyl groups or portions of Y, one or two methylene groups are optionally replaced independently of one another by O, S, CO, SO, SO.sub.2 or NR.sup.b, and one or two methyne groups are optionally replaced by N, wherein the heterocycle formed by said optional replacement is other than heteroaryl. 10. A compound of claim 1, wherein Z is selected from the group consisting of oxygen, sulfur and methylene, optionally substituted with one or two substituents selected from the group consisting of halo, hydroxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6 cycloalkyl and C.sub.3-C.sub.6 cycloalkyloxy. 11. A compound of claim 1, wherein Z is methylene. 12. A compound of claim 1, wherein R.sup.1 is a member selected from the group consisting of hydrogen, halo, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.10 cycloalkyl, (C.sub.3-C.sub.10 cycloalkyl)C.sub.1-C.sub.3 alkyl, (C.sub.3-C.sub.10 cycloalkyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.1-C.sub.4 alkyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.1-C.sub.4 alkylamino)C.sub.1-C.sub.3 alkyl, di-(C.sub.1-C.sub.3 alkylamino)C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.6 alkyloxy, C.sub.3-C.sub.10 cycloalkyloxy, hydroxy, cyano and nitro, wherein alkyl and cycloalkyl groups or portions of R.sup.1 are optionally partly or completely fluorinated. 13. A compound of claim 1, wherein R.sup.1 is a member selected from the group consisting of hydrogen, halo and C.sub.1-C.sub.6 alkyl. 14. A compound of claim 1, wherein R.sup.2 is a member selected from the group consisting of hydrogen, hydroxy, halo, C.sub.1-C.sub.4 alkyl and C.sub.1-C.sub.4 alkyloxy. 15. A compound of claim 1, wherein R.sup.2 is hydrogen or halo. 16. A compound of claim 1, wherein R.sup.3 is a member selected from the group consisting of hydrogen, halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.10 cycloalkyl, (C.sub.3-C.sub.10 cycloalkyl)C.sub.1-C.sub.3 alkyl, (C.sub.3-C.sub.10 cycloalkyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.1-C.sub.4 alkyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.1-C.sub.4 alkylamino)C.sub.1-C.sub.3 alkyl, di-(C.sub.1-C.sub.3 alkylamino)C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.6 alkyloxy, C.sub.3-C.sub.10 cycloalkyloxy, hydroxy, cyano and nitro, wherein alkyl and cycloalkyl groups or portions of R.sup.3 are optionally partly or completely fluorinated, and in cycloalkyl groups of R.sup.3 one or two methylene groups are optionally replaced independently of one another by O, S, CO, SO or SO.sub.2. 17. A compound of claim 1, wherein R.sup.3 is a member selected from the group consisting of hydrogen, halo, hydroxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkyloxy, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.10 cycloalkyl and C.sub.3-C.sub.10 cycloalkyloxy, wherein alkyl and cycloalkyl groups or portions of R.sup.3 are optionally partly or completely fluorinated, and in cycloalkyl groups of R.sup.3 a methylene group is optionally replaced by O, S, CO, SO or SO.sub.2. 18. A compound of claim 1, wherein R.sup.4 and R.sup.5 are each independently selected from the group consisting of hydrogen, halo, cyano, hydroxy, nitro, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkyloxy and C.sub.3-C.sub.10 cycloalkyl. 19. A compound of claim 1, wherein R.sup.4 and R.sup.5 are each independently selected from the group consisting of hydrogen, halo and hydroxy. 20. A compound of claim 1, wherein R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are each independently selected from the group consisting of hydroxy, halo, (C.sub.1-C.sub.6 alkyl)carbonyloxy, (C.sub.1-C.sub.6 alkyl)oxycarbonyloxy, arylcarbonyloxy, aryl-(C.sub.1-C.sub.3 alkyl)carbonyloxy, (C.sub.3-C.sub.10 cycloalkyl)carbonyloxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkyloxy, (C.sub.3-C.sub.7)cycloalkyloxy, aryloxy and (C.sub.3-C.sub.7)cycloalkyl-(C.sub.1-C.sub.3)alkyloxy, wherein alkyl and cycloalkyl groups or portions of each of R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are optionally partly or completely fluorinated. 21. A compound of claim 1, wherein R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are each hydroxyl. 22. A compound of claim 1, having the formula: ##STR00097## wherein V is oxygen or a single bond; W is C.sub.1-C.sub.6 alkylene; X is oxygen or sulfur; Y is a member selected from the group consisting of C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 hydroxyalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.10 cycloalkyl, C.sub.5-C.sub.10 cycloalkenyl, (C.sub.1-C.sub.4 alkyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.2-C.sub.4 alkenyloxy)C.sub.1-C.sub.3 alkyl and (C.sub.3-C.sub.10 cycloalkyloxy)C.sub.1-C.sub.3 alkyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions of Y are optionally partly or completely fluorinated and are optionally mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, C.sub.1-C.sub.3 alkyl and C.sub.1-C.sub.3 alkoxy, and in cycloalkyl and cycloalkenyl groups or portions of Y, one or two methylene groups are optionally replaced independently of one another by O, S, CO, SO, SO.sub.2 or NR.sup.b, and one or two methyne groups are optionally replaced by N, wherein the heterocycle formed by said optional replacement is other than heteroaryl; R.sup.1 is selected from the group consisting of hydrogen, halo, C.sub.1-C.sub.6 alkyl and C.sub.3-C.sub.10 cycloalkyl; and R.sup.3 is selected from the group consisting of hydrogen, halo, hydroxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkyloxy, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.10 cycloalkyl and C.sub.3-C.sub.10 cycloalkyloxy, wherein alkyl and cycloalkyl groups or portions of R.sup.3 are optionally partly or completely fluorinated, and in cycloalkyl groups of R.sup.3 a methylene group is optionally replaced by O, S, CO, SO or SO.sub.2. 23. A compound of claim 1, having the formula: ##STR00098## wherein V is oxygen or a single bond; W is C.sub.1-C.sub.6 alkylene; X is oxygen or sulfur; Y is a member selected from the group consisting of C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 hydroxyalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.10 cycloalkyl, (C.sub.1-C.sub.4 alkyloxy)C.sub.1-C.sub.3 alkyl, (C.sub.2-C.sub.4 alkenyloxy)C.sub.1-C.sub.3 alkyl and (C.sub.3-C.sub.10 cycloalkyloxy)C.sub.1-C.sub.3 alkyl; wherein alkyl, alkenyl, alkynyl and cycloalkyl groups or portions of Y are optionally partly or completely fluorinated and are optionally mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, C.sub.1-C.sub.3 alkyl and C.sub.1-C.sub.3 alkoxy, and in cycloalkyl groups or portions of Y, one or two methylene groups are optionally replaced independently of one another by O, S, CO or NR.sup.b; R.sup.3 is selected from the group consisting of ethyl, ethenyl, ethynyl and ethoxy. 24. A compound according to claim 1, which is isotopically labeled. 25. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound according to claim 1. 26. A pharmaceutical combination comprising a compound of claim 1, and at least one therapeutic agent selected from the group consisting of an antidiabetic agent, a lipid-lowering/lipid-modulating agent, an agent for treating diabetic complications, an anti-obesity agent, an antihypertensive agent, an antihyperuricemic agent, and an agent for treating chronic heart failure and atherosclerosis. 27. The pharmaceutical combination of claim 26, wherein the therapeutic agent is at least one antidiabetic agent. 28. The pharmaceutical combination of claim 27, wherein the antidiabetic agent is selected from the group consisting of insulin, a sulfonylurea, an insulin secretion enhancer, a biguanide, a sulfonylurea/biguanide combination, a meglitinide, a thiazolidinedione, a thiazolidinedione/biguanide combination, an oxadiazolidinedione, a PPAR-gamma agonist, a PPAR-alpha/gamma dual agonist, a PPAR-alpha/gamma/delta pan agonist, a retinoid X receptor agonist, an alpha-glucosidase inhibitor, a stimulant of insulin receptor tyrosine kinase, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose 1,6-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, an imidazoline derivative, a hepatic gluconeogenesis inhibitor, D-chiroinositol, a glycogen synthase kinase-3 inhibitor, an incretin mimetic, a glucagon receptor antagonist, GLP-1, a GLP-1 analog, a GLP-1 receptor agonist, amylin, an amylin analog or agonist, an aP2 inhibitor, a beta-3 adrenergic receptor agonist and an insulin sensitivity enhancer. 29. The pharmaceutical combination of claim 28, wherein the antidiabetic agent is selected from the group consisting of insulin, metformin, glyburide, glimepiride, glipyride, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, rosiglitazone, isaglitazone, netoglitazone, rivoglitazone, repaglinide, nateglinide, exenatide, muraglitazar, naveglitazar, tesaglitazar, peliglitazar, farglitazar, metaglidasen, sitagliptin, vildagliptin, denagliptin, saxagliptin, solabegron and pramlintide. 30. The pharmaceutical combination of claim 26, wherein the therapeutic agent is at least one anti-obesity agent selected from the group consisting of a serotonin-norepinephrine reuptake inhibitor, a norepinephrine-dopamine reuptake inhibitor, a selective serotonin reuptake inhibitor, a selective norepinephrine reuptake inhibitor, a norepinephrine releasing stimulant, an anorexiant, a dopamine agonist, an H.sub.3-histamine antagonist, a 5-HT2c receptor agonist, a beta-3 adrenergic receptor agonist, a cholecystokinin agonist, a lipase inhibitor, an antidepressant/acetylcholinesterase inhibitor combination, an anti-epileptic agent, leptin, a leptin analog or leptin receptor agonist, an NPY receptor antagonist or modulator, ciliary neurotrophic factor, a thyroid hormone receptor-beta agonist, a cannabinoid CB1 receptor antagonist, a melanin-concentrating hormone receptor antagonist, a melanocortin-4 receptor agonist and a selective muscarinic receptor M.sub.1 antagonist. 31. The pharmaceutical combination of claim 30, wherein the anti-obesity agent is at least one agent selected from the group consisting of rimonabant, orlistat, sibutramine, topiramate, zonisamide, dextroamphetamine, phentermine, phenylpropanolamine, diethylpropion, mazindol, doprexin and Axokine. 32. The pharmaceutical combination of claim 26, wherein the therapeutic agent is at least one lipid-lowering/lipid-modulating agent selected from the group consisting of a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibric acid derivative, a PPAR-alpha agonist, a PPAR-delta agonist, an acyl-coenzyme A:cholesterol acyltransferase inhibitor, probucol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a lipoprotein-associated phospholipase A2 inhibitor, a microsomal triglyceride transfer protein inhibitor, a low density lipoprotein receptor activator, a lipoxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a squalene synthase inhibitor, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, and a cholesterol ester transfer protein inhibitor. 33. The pharmaceutical combination of claim 32, wherein the lipid-lowering/lipid-modulating agent is at least one agent selected from the group consisting of pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, nisvastatin, visastatin, atavastatin, rosuvastatin, colestipol, cholestyramine, colestilan, colesevelam, fenofibrate, gemfibrozil, clofibrate, avasimibe, eflucimibe, eldacimibe, lecimibide, liothyronine, levothyroxine, rilapladib, darapladib, etomoxir, acipimox and torcetrapib. 34. A method for treating type 1 or type 2 diabetes mellitus, hyperglycemia, diabetic complications, insulin resistance, metabolic syndrome, hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic heart failure or atherosclerosis, which comprises administering an effective amount of a compound of any of claim 1 to a subject in need thereof. 35. The method of claim 34, further comprising administering, concurrently or sequentially, a therapeutically effective amount of at least one additional therapeutic agent selected from the group consisting of an antidiabetic agent, a lipid-lowering/lipid-modulating agent, an agent for treating diabetic complications, an anti-obesity agent, an antihypertensive agent, an antihyperuricemic agent, and an agent for treating chronic heart failure or atherosclerosis. 36. A method for treating type 1 or type 2 diabetes comprising administering a therapeutically effective amount of a compound of claim 1 alone or in combination with at least one other therapeutic agent selected from the group consisting of an antidiabetic agent, a lipid-lowering/lipid-modulating agent, an agent for treating diabetic complications, an anti-obesity agent, an antihypertensive agent, an antihyperuricemic agent, and an agent for treating chronic heart failure or atherosclerosis. 37. A compound of claim 1, selected from the group consisting of (2S, 3R,4R,5S,6R)-2-(2-(allyloxymethyl)-4-chloro-5-(4-ethylbenzyl)phenyl)-6-(h- ydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; 1-(5-chloro-4-(4-ethylbenzyl)-2-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hyd- roxymethyl)tetrahydro-2H-pyran-2-yl)benzyloxy)propan-2-one; (2S,3R,4R,5S,6R)-2-(4-chloro-2-((2,3-dihydroxypropoxy)methyl)-5-(4-ethylb- enzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-((2-hydroxypropoxy)methy- l)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-((prop-2-ynyloxy)methyl)- phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-((2-hydroxyethoxy)methyl- )phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-2-((2,2-difluoroethoxy)methyl)-5-(4-ethylben- zyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-((2-methoxyethoxy)methyl- )phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-((2-fluoropropoxy)methyl- )phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-((2-hydroxy-3-methoxypro- poxy)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(2-(2-(allyloxy)ethyl)-4-chloro-5-(4-ethylbenzyl)pheny- l)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-(2-(2-hydroxyethoxy)ethy- l)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-(2-(2-fluoroethoxy)ethyl- )phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-2-(2-(2,2-difluoroethoxy)ethyl)-5-(4-ethylbe- nzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-(2-(2,2,2-trifluoroethox- y)ethyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-((3-hydroxypropoxy)methy- l)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-(2-(prop-2-ynyloxy)ethyl- )phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(2-(2-(but-2-ynyloxy)ethyl)-4-chloro-5-(4-ethylbenzyl)- phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-(2-(prop-2-ynyloxy)ethy- l)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(2-(2-(allyloxy)ethoxy)-4-chloro-5-(4-ethylbenzyl)phen- yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(2-((but-2-ynyloxy)methyl)-4-chloro-5-(4-ethylbenzyl)p- henyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(2-((but-2-ynyloxy)methyl)-4-chloro-5-(4-ethoxybenzyl)- phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(2-(allyloxymethyl)-4-chloro-5-(4-ethoxybenzyl)phenyl)- -6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(2-((but-2-ynyloxy)methyl)-4-chloro-5-(4-methoxybenzyl- )phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran- 3,4,5-triol; (2S,3R,4R,5S,6R)-2-(5-(4-(allyloxy)benzyl)-2-(allyloxymethyl)-4-chlorophe- nyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(2-((but-2-ynyloxy)methyl)-4-chloro-5-(4-hydroxybenzyl- )phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; ((2R,3S,4R,5R,6S)-6-(4-chloro-5-(4-ethylbenzyl)-2-((prop-2-ynyloxy)methyl- )phenyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl acetate; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-(2-(prop-2-ynyloxy)ethox- y)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(2-(2-(but-2-ynyloxy)ethoxy)-4-chloro-5-(4-ethylbenzyl- )phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-2-(2-(cyclopentyloxy)ethoxy)-5-(4-ethylbenzy- l)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-(2-(2-fluoroethoxy)ethy- l)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(2-(3-(but-2-ynyloxy)propyl)-4-chloro-5-(4-ethoxybenzy- l)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-(2-(trifluoromethoxy)eth- oxy)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-(2-(2,2,2-trifluoroethox- y)ethoxy)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(2-((but-3-ynyloxy)methyl)-4-chloro-5-(4-ethylbenzyl)p- henyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-((2-fluoroethoxy)methyl)- phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-2-((2,2-difluoropropoxy)methyl)-5-(4-ethylbe- nzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-((prop-2-ynyloxy)methyl- )phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; and ((2R,3S,4R,5R,6S)-6-(4-chloro-5-(4-ethoxybenzyl)-2-((prop-2-ynyloxy)methy- l)phenyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl acetate; or a pharmaceutically acceptable salt thereof.

Details for Patent 7,838,498

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2027-04-02